As of the latest Form 4 filed Jul 2, 2026.
What Fennec Pharmaceuticals Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 38 most recent filings for FENC.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-02 | 2026-07-01 | Raykov Rosty Insider | SSale | −9.60K | $10.41 | $99.9K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Raykov Rosty, Insider | MExercise | +15.6K | $2.45 | $38.2K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Raykov Rosty, Insider | AAward | +2.78K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | Cioffi Christiana Marie Chief Strategy Officer | AAward | +156.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | Sayad Pierre Sargis Chief Medical Officer | AAward | +168.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | Evans Terry L Chief Commercial Officer | AAward | +168.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | Hackman Jeffrey S. Chief Executive Officer | AAward | +1.16K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | Andrade Robert CHIEF FINANCIAL OFFICER | AAward | +1.70K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | Raykov Rosty Director | SSale | −9.75K | $9.62 | $93.8K | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | Raykov Rosty, Director | MExercise | +15.6K | $2.45 | $38.2K | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-05-31 | Raykov Rosty, Director | AAward | +2.78K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-06-01 | 2026-05-31 | Cioffi Christiana Marie Chief Strategy Officer | AAward | +156.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-01 | 2026-05-31 | Sayad Pierre Sargis Chief Medical Officer | AAward | +168.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-01 | 2026-05-31 | Evans Terry L Chief Commercial Officer | AAward | +168.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-01 | 2026-05-31 | Hackman Jeffrey S. Chief Executive Officer | AAward | +1.16K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-01 | 2026-05-31 | Andrade Robert CHIEF FINANCIAL OFFICER | AAward | +1.70K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-12 | 2026-05-11 | RALLIS CHRIS A Director | SSale | −8.35K | $7.04 | $58.8K | Yes (planned) | Form 4 ↗ |
| 2026-05-12 | 2026-05-11 | RALLIS CHRIS A, Director | MExercise | +14.3K | $2.44 | $35.0K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Raykov Rosty Director | SSale | −10.8K | $6.47 | $69.8K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Raykov Rosty, Director | MExercise | +15.6K | $2.45 | $38.2K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-04-30 | Cioffi Christiana Marie Chief Strategy Officer | MExercise | +155.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-01 | 2026-04-30 | Sayad Pierre Sargis Chief Medical Officer | MExercise | +168.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-01 | 2026-04-30 | Evans Terry L Chief Commercial Officer | MExercise | +168.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-01 | 2026-04-30 | Hackman Jeffrey S. Chief Executive Officer | MExercise | +1.16K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-01 | 2026-04-30 | Raykov Rosty Director | MExercise | +2.78K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-04-30 | Andrade Robert CHIEF FINANCIAL OFFICER | MExercise | +1.70K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-26 | 2026-03-26 | Cioffi Christiana Marie Chief Strategy Officer | MExercise | +4.70K | $4.23 | $19.9K | No | Form 4 ↗ |
| 2026-03-26 | 2026-03-26 | Andrade Robert CHIEF FINANCIAL OFFICER | MExercise | +13.1K | $5.10 | $66.7K | No | Form 4 ↗ |
| 2026-02-19 | 2026-02-18 | Hackman Jeffrey S. Chief Executive Officer | MExercise | +13.7K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-19 | 2026-02-18 | Andrade Robert CHIEF FINANCIAL OFFICER | MExercise | +27.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-19 | 2026-02-18 | Andrade Robert, CHIEF FINANCIAL OFFICER | MExercise | +2.45K | $4.08 | $10.00K | No | Form 4 ↗ |
| 2026-02-02 | 2026-02-02 | Raykov Rosty Director | SSale | −10.3K | $7.76 | $80.3K | Yes (planned) | Form 4 ↗ |
| 2026-02-02 | 2026-02-02 | Raykov Rosty, Director | MExercise | +15.6K | $2.45 | $38.2K | Yes (planned) | Form 4 ↗ |
| 2026-02-02 | 2026-01-31 | Raykov Rosty Director | AAward | +5.21K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-02 | 2026-01-31 | Andrade Robert CHIEF FINANCIAL OFFICER | AAward | +1.56K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-05-02 | 2024-05-01 | Raykov Rosty CHIEF EXECUTIVE OFFICER | SSale | −2.43K | $9.11 | $22.2K | Yes (planned) | Form 4 ↗ |
| 2024-05-02 | 2024-04-30 | Andrade Robert CHIEF FINANCIAL OFFICER | AAward | +1.04K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-05-02 | 2024-04-30 | Raykov Rosty CHIEF EXECUTIVE OFFICER | AAward | +2.43K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also FENC’s full analysis or the market-wide insider trading feed. The tabs above jump to FENC’s other SEC data.
Source: SEC Form 4 filings for FENC, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.